Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase I Study to Evaluate the Safety of PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)

NCT03797040 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.

NCT NCT03797040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03797040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase I Study to Evaluate the Safety of PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
Lead sponsor
Pluristem Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2021
Completion date
December 31, 2021
Enrollment
27 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ionizing radiation exposure